The identified DryNB included seven genes (KIF2C, CCNA2, NDC80, KIF11, KIF23, ANLN and CENPM) that were significantly associated with drug sensitivity or resistance of glioma patients to the targeted therapies. Here, CENPM is linked to central nervous system cancer.